Interestingly, they value Adapt at $300m+...means even without the vaccine, we should be in for a more than healthy return.
Given some of the deals big pharma have been doleing out to small bios with promising products, HSV this could easily fetch billions...
IMHO - DYOR
updated ballieu report - target range 25-55c, page-3
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$4.69 |
Change
-0.235(4.78%) |
Mkt cap ! $72.63M | |||
| Open | High | Low | Value | Volume |
| $4.94 | $4.94 | $4.69 | $241.6K | 49.98K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 1694 | $4.50 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $4.71 | 2000 | 1 |
View Market Depth
| Last trade - 15.59pm 16/07/2025 (20 minute delay) ? |
| AVR (ASX) Chart |